Ben Braun, MD, PhD

M.D., 1998 - School of Medicine, University of California Los Angeles
  1. Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.
  2. The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.
  3. KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice.
  4. Paroxysmal cold hemoglobinuria successfully treated with complement inhibition.
  5. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.
  6. Tissue-Specific Oncogenic Activity of KRASA146T.
  7. Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.
  8. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.
  9. A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.
  10. Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
  11. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
  12. Traxtile: Interactive editing of cell tracks in time-lapse images.
  13. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
  14. PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
  15. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
  16. KIT's ship comes in.
  17. Targeting oncogenic Ras signaling in hematologic malignancies.
  18. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
  19. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells.
  20. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
  21. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.
  22. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.
  23. The SPS affair: a complex tale of illicit proliferation.
  24. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal.
  25. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
  26. Pediatric malignancies: update on sarcomas and leukemia development in children.
  27. Targeting Ras in myeloid leukemias.
  28. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.
  29. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.
  30. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.
  31. Congenital leukemia cutis with subsequent development of leukemia.
  32. The sum is greater than the FGFR1 partner.
  33. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.
  34. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
  35. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic.
  36. EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene.
  37. Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis.
  38. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.
  39. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.
  40. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1.
  41. Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen.
  42. Creation of a yeast artificial chromosome fragmentation vector based on lysine-2.